1. 3D Chromatin Alteration by Disrupting β-Catenin/CBP Interaction Is Enriched with Insulin Signaling in Pancreatic Cancer.
- Author
-
Zhou, Yufan, He, Zhijing, Li, Tian, Choppavarapu, Lavanya, Hu, Xiaohui, Cao, Ruifeng, Leone, Gustavo W., Kahn, Michael, and Jin, Victor X.
- Subjects
- *
CHROMOSOME structure , *CYTOSKELETAL proteins , *CELLULAR signal transduction , *INSULIN , *GENE expression , *PANCREATIC tumors , *CELL lines , *GENE expression profiling , *CELL differentiation , *GENOMES , *CHEMICAL inhibitors - Abstract
Simple Summary: Pancreatic cancer is a type of cancer with one of the highest mortality rates. The therapeutic methods for the treatment of pancreatic cancer are lacking. We found that when pancreatic cancer was treated with a small inhibitor, ICG-001, the 3D chromatin structures were altered. We further demonstrated that insulin signaling genes were significantly weakened after the treatment. We finally showed that when a gene looping structure was deleted, pancreatic cancer was impeded. Our work suggests that targeting aberrant insulin chromatin looping might be helpful for the treatment of pancreatic cancer. The therapeutic potential of targeting the β-catenin/CBP interaction has been demonstrated in a variety of preclinical tumor models with a small molecule inhibitor, ICG-001, characterized as a β-catenin/CBP antagonist. Despite the high binding specificity of ICG-001 for the N-terminus of CBP, this β-catenin/CBP antagonist exhibits pleiotropic effects. Our recent studies found global changes in three-dimensional (3D) chromatin architecture in response to disruption of the β-catenin/CBP interaction in pancreatic cancer cells. However, an understanding of how the functional crosstalk between the antagonist and the β-catenin/CBP interaction affects changes in 3D chromatin architecture and, thereby, gene expression and downstream effects remains to be elucidated. Here, we perform Hi-C analyses on canonical and patient-derived pancreatic cancer cells before and after treatment with ICG-001. In addition to global alteration of 3D chromatin domains, we unexpectedly identify insulin signaling genes enriched in the altered chromatin domains. We further demonstrate that the chromatin loops associated with insulin signaling genes are significantly weakened after ICG-001 treatment. We finally elicit the deletion of a looping of IRS1—a key insulin signaling gene—significantly impeding pancreatic cancer cell growth, indicating that looping-mediated insulin signaling might act as an oncogenic pathway to promote pancreatic cancer progression. Our work shows that targeting aberrant insulin chromatin looping in pancreatic cancer might provide a therapeutic benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF